Pitango, a Herzilya, Israel-based venture capital firm, held the first closing of its second dedicated healthcare fund, Pitango HealthTech II, at $175M.
HealthTech is Pitango’s dedicated health tech fund investing in seed to commercial stage companies, ranging from digital health, medical devices, techbio and diagnostics, foodtech, ag-tech, biotech and life sciences.
The first investments of the newest fund included:
- QuantHealth.ai, an AI company focused on clinical trial simulations to accelerate and de-risk drug development, and
- Nevia Bio, a FemTech company developing an AI-based biomarker platform for early detection of women’s health diseases.
Previous investments include companies such as Protai, Laguna Health, Vertos, Visby, Clew and Magenta.
The fund is led by a team comprised of:
- Ittai Harel (Managing Partner),
- Hila Karah (Managing Partner),
- Dr. Jonathan Glazer (Partner),
- Joel Schoppig (Senior Principal) and
- Dr. Seth Rudnick (Special Advisor).
Pitango HealthTech is part of the Pitango investment platform, operating alongside Pitango First and Pitango Growth Funds. Since its inception in 1993, Pitango has invested in over 250 companies and seen more than 85 become publicly traded companies, or acquired by strategic players.
FinSMEs
06/09/2023